文献速递肿瘤 PET/CT甲状腺核医学

比较[18F]氟雌二醇与[18F]氟脱氧葡萄糖正电子发射断层显像/计算机断层显像对雌激素受体阳性原发性乳腺癌病史患者乳腺癌复发的诊断灵敏度

Comparison of diagnostic sensitivity of [18F]fluoroestradiol and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for breast cancer recurrence in patients with a history of estrogen receptor-positive primary breast cancer.
PubMed 文献 · EJNMMI Res · 2020-05-24

该研究回顾性分析了先前前瞻性队列中46例雌激素受体阳性原发性乳腺癌疑似首次复发患者,比较[18F]FES与[18F]FDG PET/CT定性诊断灵敏度(以组织学诊断为标准)。[18F]FES灵敏度71.1%(32/45),[18F]FDG以阳性为阈值时80.0%(36/45),以可疑为阈值时93.3%(42/45);阳性阈值下两者无显著差异(P=0.48),可疑阈值下[18F]FDG显著高于[18F]FES(P=0.013)。作者认为当标准影像学检查结果不明确或可疑时,[18F]FES PET/CT可作为初始检查纳入再分期。

要点

  • 在45例确认复发患者中,[18F]FES PET/CT诊断灵敏度为71.1%(32/45,95%CI 55.7-83.6)。
  • [18F]FDG PET/CT以阳性为阈值时灵敏度80.0%(36/45,95%CI 65.4-90.4),以可疑为阈值时93.3%(42/45,95%CI 81.7-98.6)。
  • 阳性阈值下两种示踪剂灵敏度无显著差异(P=0.48),可疑阈值下[18F]FDG显著高于[18F]FES(P=0.013)。

核心结论

  • 对于雌激素受体阳性原发性乳腺癌且出现复发的患者,当标准影像学检查结果不明确或可疑时,再分期可包括[18F]FES PET/CT作为初始检查。

研究设计与样本

  • 回顾性分析先前评估[18F]FES PET/CT的前瞻性队列研究数据库,纳入连续患者中雌激素受体阳性原发性乳腺癌、就诊时疑似首次复发且接受[18F]FDG PET/CT的合格患者。

主要发现

  • 46例入组患者中45例确认乳腺癌复发,1例诊断为慢性肉芽肿性炎症;40例(89%)为雌激素受体阳性,4例(9%)为雌激素受体阴性,1例(2%)未进行雌激素受体检测。
  • [18F]FES PET/CT诊断灵敏度为71.1%(32/45,95%CI 55.7-83.6)。
  • [18F]FDG PET/CT以阳性为判读阈值时灵敏度为80.0%(36/45,95%CI 65.4-90.4),以可疑为阈值时为93.3%(42/45,95%CI 81.7-98.6)。
  • 以阳性[18F]FDG摄取为阈值时,[18F]FES与[18F]FDG PET/CT灵敏度无显著差异(P=0.48)。
  • 以可疑[18F]FDG摄取为阈值时,[18F]FDG灵敏度显著高于[18F]FES(P=0.013)。

临床怎么用

  • 作者认为,对于雌激素受体阳性原发性乳腺癌出现复发的患者,当标准影像学检查结果不明确或可疑时,再分期可包括[18F]FES PET/CT作为初始检查。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To compare the diagnostic sensitivity of [18F]fluoroestradiol ([18F]FES) and [18F]fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) for breast cancer recurrence in patients with estrogen receptor (ER)-positive primary breast cancer. METHODS: Our database of consecutive patients enrolled in a previous prospective cohort study to assess [18F]FES PET/CT was reviewed to identify eligible patients who had ER-positive primary breast cancer with suspected first recurrence at presentation and who underwent [18F]FDG PET/CT. The sensitivity of qualitative [18F]FES and [18F]FDG PET/CT interpretations was assessed, comparing them with histological diagnoses. RESULTS: Of the 46 enrolled patients, 45 were confirmed as having recurrent breast cancer, while one was diagnosed with chronic granulomatous inflammation. Forty (89%) patients were ER-positive, four (9%) were ER-negative, and one (2%) patient did not undergo an ER assay. The sensitivity of [18F]FES PET/CT was 71.1% (32/45, 95% CI, 55.7-83.6), while that of [18F]FDG PET/CT was 80.0% (36/45, 95% CI, 65.4-90.4) with a threshold of positive interpretation, and 93.3% (42/45, 95% CI, 81.7-98.6) when a threshold of equivocal was used. There was no significant difference in sensitivity between [18F]FES and [18F]FDG PET/CT (P = 0.48) with a threshold of positive [18F]FDG uptake, but the sensitivity of [18F]FDG was significantly higher than [18F]FES (P = 0.013) with a threshold of equivocal [18F]FDG uptake. One patient with a benign lesion showed negative [18F]FES but positive [18F]FDG uptake. CONCLUSIONS: The restaging of patients who had ER-positive primary breast cancer and present with recurrent disease may include [18F]FES PET/CT as an initial test when standard imaging studies are equivocal or suspicious.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Chae SY, Son HJ, Lee DY, et al. Comparison of diagnostic sensitivity of [18F]fluoroestradiol and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for breast cancer recurrence in patients with a history of estrogen receptor-positive primary breast cancer. EJNMMI Res. 2020. PMID: 32448947. doi:10.1186/s13550-020-00643-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。